Kedokteran & Kesehatan editorial
Open AccessOA2024
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
This study uses a Markov model to estimate that vaccinating 56.7 million US adults aged ≥60 with the adjuvanted RSVPreF3 vaccine could prevent nearly 3 million symptomatic RSV cases and over 16,000 deaths over three years.
D. Molnar; E. La; Frederik Verelst; Sara Poston; Jonathan Graham; L. Van Bellinghen; Desmond Curran· Infectious Disease and Therapy· 2024· DOI 10.1007/s40121-024-00939-w
The core problem
Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract disease in older adults, leading to considerable morbidity and mortality. Despite its impact, effective preventive measures have been limited until recently. This study evaluates the public health impact of the adjuvanted RSVPreF3 vaccine in US adults aged ≥60 years, aiming to quantify reductions in RSV-related clinical outcomes and healthcare resource use.
Innovation
A static, multi-cohort Markov model was developed to simulate RSV-related outcomes over a 3-year horizon, comparing scenarios with and without one-time RSV vaccination. The base-case analysis assumed vaccination coverage equal to that of influenza vaccines. Key epidemiological and vaccine inputs were derived from published literature and phase 3 clinical trial results for the adjuvanted RSVPreF3 vaccine. Outcomes included symptomatic RSV acute respiratory illness (RSV-ARI) cases (upper and lower respiratory tract disease), pneumonia complications, mortality, and healthcare resource use (hospitalizations, emergency department visits, outpatient visits, and antibiotic prescriptions). Sensitivity analyses were conducted to assess robustness.
Introduction
Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract disease in older adults, leading to considerable morbidity and mortality. Despite its impact, effective preventive measures have been limited until recently. This study evaluates the public health impact of the adjuvanted RSVPreF3 vaccine in US adults aged ≥60 years, aiming to quantify reductions in RSV-related clinical outcomes and healthcare resource use.
Why it matters
The findings demonstrate that the adjuvanted RSVPreF3 vaccine could substantially reduce the burden of RSV disease among US older adults. The estimated reductions in cases, complications, healthcare utilization, and mortality highlight the vaccine's potential as a key public health intervention. The consistency of results across sensitivity analyses supports the robustness of the conclusions. These results can inform vaccination policies and clinical decision-making to mitigate RSV impact in this vulnerable population.
Who should read this
Praktisi kesehatan, peneliti klinis, dan pembaca Research Digest.
Opening member content…